INNOVO's developer, Irish based company Atlantic Therapeutics Ltd, were proud to present the latest clinical research on INNOVO at the 43rd Meeting of the International Urogynaecological Association (IUGA), taking place in Vienna, Austria this week.

The study, entitled “A Randomised, Controlled, Double-Blind, Clinical Study to Compare Two Neuromuscular Stimulator Devices In Female Stress Urinary Incontinence: Effects on Symptoms and Quality of Life”, demonstrates that INNOVO is easy to use, and delivers a safe, effective, non-invasive treatment for stress urinary incontinence.

The research provides a great to support to current research which exists to support and prove the efficacy of INNOVO as a long-term, non-invasive treatment for bladder weakness, in both women and men.

See the research

Posted by: INNOVO Team, 28 June 2018

Ask us a question